NetworkNewsBreaks – Zenosense, Inc. (ZENO) Focus

NetworkNewsBreaks – Zenosense, Inc. (ZENO) Focuses on Development, Commercialization of Handheld POC Diagnostic Device to Rapidly Detect Heart Attack

Healthcare technology company Zenosense (OTC: ZENO) is primarily focused on the development and commercialization of MIDS Cardiac™ through the company’s joint venture ownership in MIDS Medical Limited (“MML”). An article discussing the company reads: “True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized. … MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer